“So we do expect broadly for our operating margin to improve over time as you see the continued top line growth and the disciplined expense management.”

In context

“designed in 2025 with the top line, building momentum in 2020 -- beyond 2025, right, '26 and beyond. So we do expect growth in '25, but our HIV business, the demand of HIV will offset the impact of Part D. Andrew Dickinson: Chris, it's Andy. I'll take the question on margin expansion. As you know, we don't provide more specific guidance for 2025 beyond what Johanna just mentioned. What we have said historically, and I've underscored, is that we are very focused on disciplined expense management. That will be true in 2025 as it is today. You've seen that in the last 2 quarters. I think on a non-GAAP basis for this quarter, if you look at our operating margin, if you strip out the CymaBay transaction, you see an improvement in our operating margin and we expect that to continue over time. So we do expect broadly for our operating margin to improve over time as you see the continued top line growth and the disciplined expense management. So thanks for the question. More details, of course, to be provided at early next year when we provide our 2025 guidance specifically. Operator: Our next question comes from Daina Graybosch at Leerink Partners. Daina Graybosch: It's for Kite. FDA's ODAC recently had 2 important meetings of relevance for multiple myeloma and CAR-T there. One, dealt with the early death risk from CARVYKTI and ABECMA. And the second was to recommend MRD as an intermediate endpoint for accelerated approval in multiple myeloma. And I wonder how you're thinking about both of these ODACs in relation to anito-cel in your earlier line trial design. Daniel O'Day: Thanks, Daina. We've got Cindy Perettie here, so we'll go right over to her. Cindy Perettie: Thanks, Daina. So if I start off with the early line ODAC”